• Browse Industries
• Health Care

• FDLI SmartBrief
• News
• Press Releases
• SmartBlogs
• Topics
• FDA
• Generic drugs
• Medical devices
• Nutrition
• Stem Cells
• Vaccines
• Jobs
• View Job Listings
• Post a Job
• Job Listings FAQ's
• Most Clicked Stories
• FDLI News
• FDLI Reader Polls
• Archive
• RSS

• Find/Post Jobs

• Partner With Us

• Advertise

• About SmartBrief

• Reader Polls

Latest News

Oncolytics says it sold $12.8M in stock and options to fund trial of cancer drug Reolysin -- South Florida Sun-Sentinel.com

Sun-Sentinel (Fort Lauderdale, Fla.) | 7 hours 44 minutes ago

NEW YORK (AP) — Canadian drug developer Oncolytics Biotech Inc. said Monday it raised $12.8 million through a sale of stock and options.... (more)

Zeroing In On What's Important

Forbes | 8 hours 5 minutes ago

Pfizer's Amy Schulman on how she makes the most of every minute.... (more)

US HOT STOCKS: LDK Solar, Zions Bancorp, IBasis

Wall Street Journal, The | 8 hours 7 minutes ago

U.S. stocks rose Monday, as the Dow Jones Industrial Average gained 125 points to 10443, the S&P 500 climbed 14 points to 1106 and the Nasdaq Composite Index gained 29 points to 2175. Among the companies whose shares are actively trading in the session are LDK Solar Co. Ltd. (LDK), Zions Bancorp (ZION) and iBasis Inc. (IBAS).... (more)

Judge Dismisses Second Case Involving Merck's Fosamax

Wall Street Journal, The | 8 hours 14 minutes ago

NEW YORK?A federal judge dismissed the second of three so-called "bellwether" cases over Merck & Co.'s osteoporosis drug Fosamax.... (more)

GlaxoSmithKline pulls application for new drug use

Boston Globe, The | 8 hours 14 minutes ago

TRENTON, N.J.British drugmaker GlaxoSmithKline PLC said Monday it is temporarily withdrawing its application for U.S. approval of a drug to prevent prostate cancer.... (more)

Merck claims win in Texas Vioxx suit

Philadelphia Inquirer, The | 8 hours 15 minutes ago

WHITEHOUSE STATION, N.J. - Merck & Co. said today that a district court judge in Texas dismissed all claims in a state Medicaid lawsuit over the painkiller Vioxx.... (more)

Salix Pharmaceuticals completes stock offering for 5.5 million shares

Hartford Courant (Conn.), The | 8 hours 21 minutes ago

NERALEIGH, N.C. (AP) ? Salix Pharmaceuticals Ltd. said Monday it completed its public offering of 5.5 million shares of common stock.... (more)

Wire Business News

Sacramento Bee (Calif.), The | 8 hours 24 minutes ago

NERALEIGH, N.C. -- Salix Pharmaceuticals Ltd. said Monday it completed its public offering of 5.5 million shares of common stock.... (more)

Britain's GlaxoSmithKline pulls application to sell enlarged prostate drug for blocking cancer

Chicago Tribune | 8 hours 45 minutes ago

TRENTON, N.J. (AP) ? British drugmaker GlaxoSmithKline PLC said Monday it is temporarily withdrawing its application for U.S. approval of a drug to prevent prostate cancer.... (more)

BioPharma Today: Latest News From PharmAsia News - Pfizer, Japan Generics, Korea FTA

BioPharma Today | 8 hours 48 minutes ago

Pfizer Ahead Of Guidance In India, President Of Established Products Business Unit David Simmons Tells PharmAsia News. ... ... (more)

Vaccines on horizon for AIDS, Alzheimer's, herpes

Yahoo! | 8 hours 48 minutes ago

MARIETTA, Pa. ? Malaria. Tuberculosis. Alzheimer's disease. AIDS. Pandemic flu. Genital herpes. Urinary tract infections. Grass allergies. Traveler's diarrhea. You name it, the pharmaceutical industry is working on a vaccine to prevent it.... (more)

Pharmasset: hepatitis C drug trial will continue

Fort Worth Star-Telegram (Texas) | 8 hours 54 minutes ago

The Associated Press NEW YORK ? Pharmasset Inc. said Monday that it will continue enrolling patients in a clinical trial of RG7128, a drug that is designed to treat the liver disease hepatitis C.... (more)

387 Stories  |   RSS Feed

Sign up for FDLI SmartBrief

Latest Blog Postsview more

Job Listingsview more

Companies in the news

© 1999-2009 SmartBrief, Inc. |  Terms of Use |  Send Feedback |  Frequently Asked Questions (FAQ) |  Privacy and Legal Information

About SmartBrief |  Advertise with SmartBrief |  Sign up for Newsletters |  Partner with SmartBrief